TELA Bio (TELA) Preferred Stock Liabilities (2018 - 2019)
TELA Bio's quarterly Preferred Stock Liabilities came in at $145.4 million in Q3 2019, up 67.32% year-on-year from $86.9 million in Q3 2018, and up 327.54% quarter-over-quarter from $34.0 million in Q2 2019.
TELA Bio has reported Preferred Stock Liabilities for 2 years, with the latest figure at $145.4 million in Q3 2019.
- For the quarter ending Q3 2019, Preferred Stock Liabilities rose 67.32% year-over-year to $145.4 million; the trailing twelve-month figure through Sep 2019 stood at $145.4 million (up 67.32% YoY), and the FY2018 full-year result was $1.6 million, down 94.7% from the prior year.
- Preferred Stock Liabilities for Q3 2019 stood at $145.4 million, up from $34.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $145.4 million in Q3 2019, with the low at $1.6 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | TELA Bio | 13.26 Mn | -26.28 Mn | 12.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 145.38 Mn |
| Jun 30, 2019 | 34.01 Mn |
| Dec 31, 2018 | 1.64 Mn |
| Sep 30, 2018 | 86.89 Mn |